{
    "ticker": "MREO",
    "name": "Mereo BioPharma Group plc",
    "description": "Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for patients with rare diseases and oncology indications. Founded in 2015 and headquartered in London, Mereo aims to address significant unmet medical needs through its robust pipeline of product candidates. The company specializes in developing therapeutics that target key biological pathways involved in disease progression. Mereo's lead product candidates, including etigilimab and alvelestat, are designed to treat conditions such as obesity and chronic obstructive pulmonary disease (COPD). Mereo's approach is centered on leveraging advanced science and technology to deliver meaningful therapies that enhance patient outcomes. The company's commitment to building partnerships with renowned institutions and pharmaceutical companies enhances its ability to bring innovative solutions to market. Mereo is dedicated to advancing healthcare by prioritizing patient-centric approaches and fostering collaborations that drive scientific progress. With a strong emphasis on research and development, Mereo BioPharma is positioned to make a significant impact in the biopharmaceutical landscape.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "London, United Kingdom",
    "founded": "2015",
    "website": "https://www.mereobiopharma.com",
    "ceo": "Dr. Denise Scots-Knight",
    "social_media": {
        "twitter": "https://twitter.com/MereoBioPharma",
        "linkedin": "https://www.linkedin.com/company/mereo-biopharma/"
    },
    "investor_relations": "https://www.mereobiopharma.com/investors",
    "key_executives": [
        {
            "name": "Dr. Denise Scots-Knight",
            "position": "CEO"
        },
        {
            "name": "Dr. Michael W. P. M. Peters",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Product Candidates",
            "products": [
                "Etigilimab",
                "Alvelestat"
            ]
        }
    ],
    "seo": {
        "meta_title": "Mereo BioPharma Group plc | Innovative Therapies for Rare Diseases",
        "meta_description": "Explore Mereo BioPharma Group plc, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for rare diseases and oncology. Learn about our product pipeline and commitment to patient-centric solutions.",
        "keywords": [
            "Mereo BioPharma",
            "Biopharmaceuticals",
            "Rare Diseases",
            "Oncology",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What is Mereo BioPharma known for?",
            "answer": "Mereo BioPharma is known for developing innovative therapeutics for rare diseases and oncology indications."
        },
        {
            "question": "Who is the CEO of Mereo BioPharma?",
            "answer": "Dr. Denise Scots-Knight is the CEO of Mereo BioPharma Group plc."
        },
        {
            "question": "Where is Mereo BioPharma headquartered?",
            "answer": "Mereo BioPharma is headquartered in London, United Kingdom."
        },
        {
            "question": "What are Mereo BioPharma's main product candidates?",
            "answer": "Mereo BioPharma's main product candidates include Etigilimab and Alvelestat."
        },
        {
            "question": "When was Mereo BioPharma founded?",
            "answer": "Mereo BioPharma was founded in 2015."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "INCY",
        "BMRN"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "CLVS",
        "SNY"
    ]
}